Monthly Letter August – Production Underway and Focus on Autumn Implementations

From production to active Dosell units
The availability of new Dosell units has been a limiting factor during parts of the first half of the year. With production now underway and the first larger deliveries completed, we have reached an important milestone.

At the same time, production and delivery are only the beginning of the commercial process. The long-term value of our business model is created when Dosell units are installed, activated and begin generating recurring revenue.

Our focus during the autumn is therefore on shortening and streamlining the entire process from agreements and customer decisions to implementation and active use.

This is also important from a capital perspective. The faster a produced unit can move from inventory to active use with a customer, the more efficiently we can use our working capital while continuing to build our recurring revenue base.

Sweden – focus on implementation and scaling
In Sweden, we continue to work with municipalities at different stages of the implementation process. Activity levels have naturally been lower during the summer, but customer dialogue, planning and preparations for upcoming launches have continued.

In municipal health and social care, the implementation of medication dispensers normally takes place in stages. An initial implementation is followed by training, organisational adoption and gradual expansion to more users and operations.

This makes expansion within existing customers at least as important to our growth as new municipal launches. Our work therefore focuses both on bringing more municipalities onto Dosell and on supporting existing customers in gradually expanding their use of the solution.

The Netherlands – preparations for continued scaling
The holiday period has also affected the pace of customer implementations in the Netherlands. During August, work continued to prepare upcoming rollouts, develop customer dialogues and ensure that the new generation of Dosell can be introduced in a structured way.

The Netherlands remains an important market for iZafe Group. Our local organisation enables us to work closely with both existing and new healthcare organisations, while also allowing us to bring experience from Europe’s most mature market for medication dispensers into our other markets.

The focus going forward is on converting the commercial activity that has been built up into more implementations and active units.

Other markets – continued partner activities
Across our other markets, activities continue primarily through local partners. In Norway, we continued our work during August with a focus on training, integrations and support in ongoing municipal processes. In Finland, work continues around market development, procurement processes and joint sales activities. In Iceland, our partner spent August preparing for the market launch, with a focus on logistics, activation and local marketing materials.

A higher pace into the autumn
September has started with a clearly higher level of activity than during the summer months. Customer meetings, implementations, training activities and partner initiatives have picked up again across several of our markets.

What matters now is that this activity is gradually reflected in more installed and active Dosell units.

As we described in our Q2 report, the time from agreements and customer decisions to revenue-generating units was longer than planned during the first half of the year. With a larger production volume now moving into the market, our focus is therefore firmly on execution – from delivery to installation, active use and recurring revenue.

The autumn will be an important period, with a clear focus on implementation, scaling and continuing to build our recurring revenue base.

We remain focused on making Dosell a natural part of the future of medication management.

Thank you for following our journey.